ClinicalTrials.Veeva

Menu

The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

Sun Yat-sen University logo

Sun Yat-sen University

Status

Completed

Conditions

Nasopharyngeal Neoplasms

Treatments

Other: the number of circulating tumor cells

Study type

Observational

Funder types

Other

Identifiers

NCT02505139
SYSUCCCTC

Details and patient eligibility

About

A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma (mNPC) patients is not unknown. Through the observational prospective clinical trial, sensitivity, specificity, positive and negative predictive values of CTC in diagnosis of mNPC patients will be gained. Further, the value of CTC in outcome prediction of mNPC patients will be uncovered.

Enrollment

166 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically or radiologically confirmed nasopharyngeal non-keratinizing carcinoma (WHO II, III).
  • NPC patients with distant metastasis including synchronous distant metastasis at diagnosis and metachronous distant metastasis after radical treatment.
  • A Karnofsky performance status score more than 70.
  • The participants provided written informed consent.

Exclusion criteria

  • A history of previous or synchronous malignant tumors.
  • Suffering from severe mental illness synchronously.
  • Suffering from severe heart or lung diseases.
  • Obvious abnormality in liver and renal function.
  • Women in pregnancy or breastfeeding.

Trial design

166 participants in 1 patient group

Study Group
Treatment:
Other: the number of circulating tumor cells

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems